Augmented Reality Navigation in TKRAt Landmark Hospitals

Telugu super news,Hyderabad, april 18,2024:Total Knee Replacement (TKR) is a very common and highly successful surgery. Success rates are over 95% and average durability is over 20 – 25 years. In India every year about 3 lakh TKRs are performed.

To improve the outcomes further ‘accuracy’ of implant placement is one way. To do that several
techniques were developed.

What is AUgmented Reality TKR technology:

Speaking to the media Dr. Sudhir Reddy, Chief Orthopeadic Surgeon, Landmark Hospitals
said, by using the cutting edge tracking system and Augmented Reality tools to give the
surgeon ability to achieve accurate alignment, projects Augmented Reality vision to the surgical
field, making accurate placement of implants seamless without having to use invasive tools.Also
the surgeon is in total control of the procedure white the technology only assists or guides.

AR technology s the latest and most advanced technological development in the field of TKR. It
gives the accuracy of Robotic TKR without the damage and restrictions associated with Robotic
TKR. Also because of perfect alignment in implant fixation, the longevity of TKR is likely to

AR TKR Advantages over Robotic TKR

Augmented Reality TKR Robotic TKR
Accuracy Good Good
Invasive (damage to tissues) Less More
Incision Small Large
Complications such as
frcature, infection

Less More
Surgeon Control Full Partial
Implant Choice Complete No choice
Radiation risk Nil Yes (CT scan)

In Telangana and Andhra Pradesh – 1st Augmented Reality TKR was conducted at
Landmark hospitals on 27th Feb’24 by Dr Sudhir Reddy’s team. Now nearly 70 surgeries
have been done using AR technology.

Patient experiences:
Mr Prasad Reddy, 64 yrs had bilateral TKR using AR technology one week ago. He says ‘ I
underwent both knee replacement surgeries two days ago. I have very minimal pain and already
able to walk independently without any support. I am discharged with in two days. I am able to
climb stairs also. I am surprised at such quick recovery and minimal pain.

Mrs Saroja, 58 yrs said ‘after undergoing TKR using AR technology I got Discharged With in
one day and have been walking independently. After 2 days I even did some work in kitchen.
Initially i was so afraid of pain and had postponed the surgery for a long time and suffered. Now
i feel like it is new life and I am surprised at how quick the recovery is.

Lupin Receives Approval from U.S. FDA for Valbenazine Capsules

Telugu super news, April 8, 2024: Global pharma major Lupin Limited (Lupin) today announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application (ANDA) for Valbenazine Capsules, 40 mg and 80 mg, to market a generic equivalent of Ingrezza® Capsules, 40 mg and 80 mg, of Neurocrine Biosciences, Inc. Lupin is one of the first ANDA applicants and is eligible for 180 days of shared generic exclusivity.  The product will be manufactured at Lupin’s Nagpur facility in India.

Valbenazine Capsules, 40 mg and 80 mg (RLD Ingrezza®) had estimated annual sales of USD 1621 million in the U.S. (IQVIA MAT February 2024).

9M Fertility by Ankura HospitalRedefines Success, and Embraces Growth in the Last one year

Telugu super news,Hyderabad,6th April, 2024:Hyderabad, India – April 4, 2024 – 9M Fertility, a pioneering division of Ankura Hospital for Women and Children, proudly celebrates its first anniversary with groundbreaking achievements in the field of assisted reproduction.

Ankura Hospital, renowned for its commitment to delivering high-quality healthcare services, introduced 9M Fertility as a beacon of excellence in infertility care. Over the past year, 9M Fertility has emerged as a leader in the industry, boasting an exceptional overall success rate of 79.5%.

In recent months, 9M Fertility has achieved remarkable success rates, with a soaring 82% success rate in the last three months and a consistent 83% success rate over the last six months. These figures far surpass global averages for fertility treatments, setting a new standard for excellence in reproductive medicine.

The success of 9M Fertility is attributed to its commitment to four pillars: Ethical and transparent service, Individualized approach, Evidence-based treatments, and Advanced technology. By leveraging advanced fertility treatment options such as Pre-genetic tests (PGT) and the Endometrial receptive array (ERA), 9M Fertility ensures higher chances of success and healthy outcomes for couples undergoing infertility treatments. 

Pre-genetic tests (PGT), such as PGT-A, PGT-SR, and PGT-M, test the embryos for genetic abnormality before transplantation to the uterus. Genetic conditions in family, age, and other causes may predispose some couples to having babies with chromosomal abnormalities, such as Down’s syndrome.

PGT tests not only assure higher chances of success for infertility treatments but also ensure healthy embryos. The Endometrial receptive array is yet another such test to achieve a higher success rate of fertility treatments. In ERA the uterus lining of the mother-to-be is first examined microscopically to ensure that it is prepared well to receive the embryo, thereby increasing chances of successful implantation.

A long list of advanced infertility treatments such as In-vitro fertilization (IVF), In-vitro Maturation (IVM), and Fertility preservation options for couples/individuals who want to delay pregnancy is provided by 9M. What is miraculous is that men who had azoospermia, and were not able to ejaculate sperms effectively due to some underlying problem, have been able to conceive with their own gametes at 9M Fertility.

In usual cases, donor sperms are used in such scenarios, but by the availability of advanced tests such as TESA, M TESE at 9M Fertility sperms can be retrieved from fathers-to-be, adding much to the joy of couples.

Dr. Sreevani Kotha, Director and Head of 9M Fertility, emphasizes the importance of personalized care and guidance provided to each couple throughout their infertility journey. “Each case of infertility is unique,” says Dr Kotha, “and our expert team at 9M Fertility is dedicated to helping couples understand and tackle infertility with the best available options tailored to their needs.”

As infertility rates continue to rise in India and globally, 9M Fertility is poised for expansion to meet the growing demand for specialized infertility care. Dr Durga Prasad, Senior Paediatrician and Cluster Medical Director at Ankura Hospital announces plans for new 9M Fertility centres in Bhubaneswar, Nashik, Vijayawada, Khammam, Tirupati, and additional locations in Hyderabad and Pune and thereby will take the tally up to 11 centres from just 2 centres presently- one each in Hyderabad and Pune.

Ankura Hospital is trusted by thousands of families for women and child healthcare,” says Dr Prasad, “and we are excited to extend our trusted and predictable solutions for infertility through 9M Fertility to more communities.”

With its unwavering commitment to building families, nurturing dreams, and bringing hope to those in search of the greatest gift of all – the gift of life, 9M Fertility continues to redefine the landscape of assisted reproduction.

PhonePe Partners with Star Health Insurance to Offer Insurance with Monthly Payment Options

Telugu super news, National, April 32024: PhonePe today announced a partnership with Star Health and Allied Insurance Company Ltd. (Star Health Insurance), India’s largest retail health insurance Company, to offer customers health insurance with a monthly and annual payment option. With this partnership, PhonePe users will now be able to avail of ‘Star Comprehensive Insurance Policy’ on the PhonePe app with coverage up to Rs.1 Crore. Having previously disrupted the market with its motor insurance products, with this launch, PhonePe further expands the options available to its users in the health insurance category.

Through this partnership, for the first time, Star Health Insurance’s Comprehensive Health Insurance will be offered to customers with a monthly premium payment plan, pioneered by PhonePe – a first-of-its-kind initiative in the industry. Users can also opt to pay their premium with the UPI AutoPay mandate and enjoy added convenience. This move was driven by a critical insight that smaller monthly payments ease the financial burden for users while empowering and enabling them to opt for more extensive insurance coverage without stretching their finances.

Star Comprehensive Insurance Policy is a power-packed insurance plan with benefits including the most popular OPD and maternity coverage. Market research conducted with PhonePe’s user base indicates that these two features were the most preferred by customers while buying health insurance. Star Comprehensive Health Insurance Policy is an end-to-end health insurance policy with sum insured available up to Rs.1 crore. The policy covers road ambulance and air ambulance expenses, out-patient medical consultation up to the limits, out-patient coverage for dental and Ophthalmic treatment, delivery expenses, organ donor expenses, provides coverage for newborn babies, including any congenital disorders, from day one of birth and vaccination expenses of the new born until the baby completes one year. Mental well-being is covered up to the sum insured. The policy does not impose sub-limits for day care procedures. Accidental death and permanent total disablement is covered up to 1 crore.

Star Comprehensive Health Insurance Policy also offers wellness programmes that provide discounts on premiums and condition management programmes. Furthermore, the policy provides an annual health check-up, automatic restoration of the sum insured up to 100%, and a cumulative bonus, payable up to 100% of the basic sum insured.

Speaking on the partnership, Vishal Gupta, CEO of PhonePe Insurance said “PhonePe is excited about this partnership with Star Health. Star’s differentiated benefits combined with PhonePe’s distribution, customer centric approach and simple DIY journeys will help turbocharge insurance adoption and penetration in the country. We are on a mission to help turn India from an underinsured nation to one that is adequately insured and view this partnership with Star as a crucial milestone in this journey.”

Speaking on the partnership, Anand Roy, MD and CEO of Star Health Insurance, said, “We are excited to partner with PhonePe and offer health insurance targeted at Gen Z and Millennials since people in that group are digital natives. The partnership between Star Health Insurance and PhonePe will provide consumers with a hassle-free payment option that is light on the pocket and at the same time meets their wellness needs. Today, health insurance has become a necessity. Given the high medical inflation in the country, it has become crucial to have an all-inclusive health cover that can protect at every stage of an individual’s life. At Star, we believe in keeping our customers healthy, and towards that end, customers buying our policies will not just get insurance but will also have access to free teleconsultations, homecare, and nutritionists, among other services. We look forward to expanding our digital reach through this partnership.”

Users can purchase the policy via the PhonePe app by clicking on the Health Insurance option, selecting the members to be insured, the desired sum to be insured and the payment tenure. Here, they can choose either monthly EMIs or annual payments and then select the  policy of their choice. Once they opt for the policy, the customer’s have to fill in their details, such as name, age, and gender, followed by the health history of all members to be insured. This will be followed by a regulator mandated Know Your Customer (KYC) form and declarations, once the payment is completed.

Star Health, in association with PhonePe, plans to roll out more such innovative offerings across its indemnity and benefit products.

Wipro GE Healthcare Announces Investment of Over INR8000 Crores in Manufacturing Output & Local R&D Over Next 5 Years

Telugu super news,India,March,2024: Wipro GE Healthcare, a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, today announced an investment of over INR8000 Crores in manufacturing output & local R&D over next 5 years. Poised for exponential growth, MedTech, the Sunrise Sector is thriving with the hospital industry in India, accounting for 80% of the total healthcare market and witnessing strong investor demand locally and globally. This strategic investment bolsters Wipro GE Healthcare’s local manufacturing footprint to address the growing domestic and international market and will build supply chain resiliency for the organization.  As a part of this investment, the Wipro GE Healthcare ‘Made in India’ PET CT Discovery IQ will be exported to 15 countries. Additionally, the ‘Made in India’ Revolution Aspire CT, Revolution ACT and MR breast coils will be manufactured ‘In India for the World’.  

India is among the top 20 global markets for medical devices in the world. Wipro GE Healthcare is among the first MedTech companies to ‘Make in India – for India and the world’ over past three decades, investing upwards of over $4Billion in R&D and manufacturing output in India since inception. Over the decades, the organization has fostered a strong local supplier ecosystem of MedTech component manufacturing – covering capabilities like plastics, EMS, machining, castings, 3D printing – contributing $1M supplier Labor hours. The investment will include creation of additional 400,000 labor hours.

Azim Premji, Chairman, Wipro GE Healthcare, Chairman, Wipro Enterprises and Chairman Azim Premji Foundation, said, “India is riding the resurgent growth in the healthcare industry and rapidly expanding MedTech sector. With ‘Make in India’, we are witnessing an exponential expansion of manufacturing footprint in the country, strengthening  India’s capability as the MedTech hub of the world. Wipro GE Healthcare has been committed to this localization journey for over three decades and this strategic investment is  testament to our vision for this sector.”

Peter J. Arduini, President and CEO, GE HealthCare said, “India is a high potential, high priority market for GE HealthCare globally. In fact, we are among the first MedTech companies to ‘Make in India – for India and the World’. We will continue to invest in expanding India’s domestic capabilities and its global footprint in MedTech manufacturing and R&D. Today’s announcement is aligned with our strategic vision to deliver precision innovation globally and accelerate India’s position as ‘MedTech innovation and manufacturing hub for India and for world markets.”

Chaitanya Sarawate, Managing Director, Wipro GE Healthcare and President & CEO, GE HealthCare South Asia said, “Innovating in India and Making in India – for India and for the World, has always been a priority for us, evident in our trajectory and investments over past three decades. We have fostered a strong innovation track record, a local supplier ecosystem and built a portfolio of world class products in India, for India and the world. As a local partner we are bullish about India’s potential and its journey to be ‘Atmanirbhar’ and a key cog in the resilient global supply chain. As India envisions to be among top five global manufacturing hubs in terms of value and technology for Medical Devices in the coming years, we are committed to the national healthcare agenda.”

Currently, the organization has four manufacturing plants in Bengaluru. All four manufacturing plants are export plants – the latest one established in March 2022 with an investment of a little over INR100 crore under the Indian government’s PLI Scheme. 

GE HealthCare is among the first healthcare companies to start an R&D center in India over three decades back. The Healthcare Technology Center India (HTCI) is GE HealthCare’s largest R&D center outside of the USA, situated in John F. Welch Technology Centre (JFWTC), Bengaluru. The organization also has collaborations with leading academic institutions in the country to further research. In January 2024, GE HealthCare signed an MoU with Indian Institute of Science (IISc) to advance MedTech innovation from India – for India and the world.  

FUJIFILM India Installs its first ever State-of-the-Art Open MRI Machine in Hyderabad at Vijaya Diagnostic Centre

Telugu super news,Hyderabad, 22 March 2024: Expanding access to advanced diagnostic imaging, FUJIFILM India has announced the installation of its groundbreaking Open MRI machine “APERTO Lucent” at Vijaya Diagnostic Centre- India’s Largest Integrated B2C Diagnostic Chain. The event was graced by Mr. Koji Wada, MD of FUJIFILM India and Mr. Chander Shekhar Sibal, Sr. Vice President & HOD – Healthcare Business -FUJIFILM India, along with Mr. Sheshadri Vasan, Chief Operating Officer of Vijaya DiagnosticCentre. This partnership marks a significant step towards advancing patient-centric imaging technology.

The APERTO Lucent is a new age, Prime open MRI device which is equipped with IP-RAPID – a modern day technique that reduces scan times while maintaining high image quality by employing under sampling and image reconstruction with iterative processing which will result in improved image quality with higher spatial resolution. The design of APERTO Lucent will provide high speed solutions combined with better patient experience.

Revolutionizing diagnostic centres and healthcare facilities, this state-of-the-art machine boasts a groundbreaking 0.4T static-field-strength permanent magnet and a sleek gantry, propelling Magnetic Resonance Imaging into a new era of sophistication. Provides swift scans with accelerated speeds, all at a low running cost and an attractive initial investment with no additional infrastructure required. Its simplified installation process and reduced construction needs expedite setup, ensuring operational readiness in record time. Designed for space efficiency, its compact form is perfect for healthcare facilities with limited space. With vigilant customer support, uninterrupted functionality, round-the-clock monitoring, and enhanced maintenance efficiency, the machine empowers healthcare professionals to prioritize patient care.

Adding on, Mr. Chander Shekhar Sibal, Sr. Vice President & HOD, Healthcare Business, FUJIFILM India, said, “FUJIFILM India has been at the forefront of MRI technology with consistent development where we always aim to find the next breakthrough in the form of higher resolution and crystalline imaging, aiding in more accurate diagnoses. At the same time, we’re also focused on patient-centric designs as we build comfortable MRI machines, reducing claustrophobia and anxiety during scans. Therefore, APERTO Lucent elevates industry benchmarks by combining both aspects, redefining the sophisticated MRI field. Its installation will broaden our technological footprint in the country, offering a streamlined, patient-centric and economical solution for our partners like Vijaya DiagnosticCentre.”

Taking patient friendliness to a notch high, APERTO Lucent’s single-pillar MRI structure provides a panoramic open view, significantly reducing patient anxiety. It also features a wide, lateral table with a soft sound operation to create a comfortable examination environment. Moreover, the True OPEN Bore design of the system reduces the risk of claustrophobia while accommodating patients of diverse body types.

Expressing enthusiasm about the partnership, Mr. Sheshadri Vasan, Chief Operating Officer of Vijaya DiagnosticCentre, stated, “We’re proud to be partnering with FUJIFILM India as we share the common goal of providing quality diagnostic solutions to the people. Integrating this advanced Open MRI machine into our arsenal will assist us in prioritizing comfort while maintaining top-notch diagnostic accuracy, ensuring the best possible outcomes for our patients. At Vijaya DiagnosticCentre, our objective is to deliver accessible healthcare services and this installation will transform the way we serve throughout the region.”

The collaboration between FUJIFILM India Healthcare Division and Vijaya DiagnosticCentre reflects a shared commitment to advancing healthcare technology and enhancing patient care in the region.

HMD develops safety needle syringes to protect healthworkers against needle-stick injuries in Telangana

Telugu super news,Hyderabad, March 21, 2024: Hindustan Syringes and Medical Devices (HMD), one of the leading manufacturers of disposable and AutoDisable syringes in the world, has launched the most innovative and first-of-its kind Dispojekt single use syringes with safety needle in Hyderabad, propelling India towards ‘atmanirbhar’ and becoming global powerhouse in medical devices.

The launch aligns with India’s efforts to become a self-reliant hub for medical device
manufacturing and exporting. Dispojekt is expected to bring about a positive financial impact
on the healthcare sector by reducing healthcare worker injuries and associated costs.
With the revolutionary Dispojekt safety syringes, HMD aims to reduce prevalence
of accidental Needle Stick Injuries (NSIs) among health workers, reduction of infection
control cost and that of disposal and training, offering a long term positive financial impact
on the healthcare sector. Domestic manufactured, technologically advanced products
will provide India a global edge in the realm of R&D and leapfrog indigenous players
to meet the highly demanding global market for sharp injury prevention syringes. 

The use of safety needles in healthcare settings offer numerous cost benefits. They reduce
healthcare worker injuries, lowering costs from potential disease treatment and potential
long-term health issues. By minimizing needle stick injuries, they also decrease expenses for
post-exposure prophylaxis and associated healthcare costs. Moreover, safety needles
mitigate compensation claims, absenteeism, and can lead to lower health insurance
premiums, while also reducing product and packaging footprints for cost and environmental
savings. They assist in creating a safer and more reliable workplace environment for
healthcare workers. 
“Equipped with a safety shield (SIP Shield), Dispojekt syringe addresses critical concerns of
needle stick injuries and reaffirms our commitment as market leader towards excellence in
healthcare. It is a great outcome of our Make in India resolve as envisioned by Prime
Minister Narendra Modi to realize the goal of Viksit Bharat,” said Mr Rajiv Nath, Managing
Director, HMD, adding that India is all poised to become a global powerhouse in
manufacturing and exporting of medical devices in sync with the spirit
of Atma Nirbhar Bharat.

HMD indigenously develops and launches revolutionary Dispojekt safety needle syringes in
Hyderabad and Vijayawada to curb the menace of NSI
There is significant headroom for innovation and growth in the medical devices
industry and the future of healthcare technology rests on robust R&D. With the disposable
syringe market size in India estimated to be over 5 billion units per year and 5-6
billion needles, 80 % of which are in the hands of private sector players. “We aim for 60-
70 % market share in the next three years, thanks to our innovative Dispojekt,” informed the
Executive Director, Mr Sohail Nath.
“HMD believes in delivering the best at the most competitive costing. Dispojekt safety needle
syringes are going to be the game changer in the Global fight against NSIs. We are aiming
to initially produce 200 million syringes and needles per annum for which we have invested
approximately Rs 70 cr in the first phase,” revealed Mr Sohail.
“In the second phase, we will increase the capacity to 300 million pieces per annum by
investing another Rs 10 crore to Rs 15 crore,” added Mr Sohail, sounding buoyant over
expected return on investment over the next five years as HMD is a debt-free financially
strong manufacturer and the product development has been financed from
internal resources without any grants.
As one of the most reputed medical device manufacturers with multiple state-of-the-art
manufacturing facilities in Faridabad, Haryana, HMD produces over 4 billion injection
needles per annum, catering to the needs of its primary markets comprising India, Europe,
US, Middle East, and its secondary markets of South-East Asia and Africa.
Talking about managing inventory and distribution of Dispojekt safety needle
syringes, Mr Sohail, said that HMD has a national distribution network of over 9500 dealers
and has over 60 contractual stock points in key metropolitan, Tier I and Tier II cities which is
assisted by their dedicated sales force, ensuring that supply chain management is
uninterrupted as has been the case for its Dispovan brand syringes with rapid delivery
and short term quick delivery and turn around cycle.
Reflecting further, he said that Dispojekt safety needle syringes will not only further
strengthen our position as market leader but will give a boost global collective efforts of
WHO to check NSIs leading to transmission of blood borne disease, like Hepatitis B, C
and HIV among healthcare personnel, betting on its quality, uniqueness and affordability.
“Dispojekt safety needle syringes have been designed to be affordable for the developing
world including India and are nearly half the cost of safety single use syringes used in the
USA and Europe where 100 percent usage is mandatory by legislation,” informed Mr Sohail.

As per a publication in International Journal of Community Medicine and Public Health, the
overall prevalence of NSIs in India in 2021 was 20.1 %. It has been observed that
NSIs prevalence among nurses was 31.3 %, technicians 37.5 %, ward boys and other staff
15 %, and sweepers of public and private hospitals 15.6 %.
According to research, the prevalence of NSIs among healthcare workers in India is between
57% and 73%. In fact, approximately 54% of NSIs are reported because of
using hypodermic needles. Many instances of NSIs go unreported, making it a way more
serious problem than it appears. To shield frontline healthcare workers from the dangers of
NSIs, we at HMD have pioneered a single-use syringe with safety needle –Dispojekt.
The Center for Disease Control and Prevention, US, has estimated that only 10 % of NSIs
injuries are reported. In developing countries, which have the highest global prevalence of

HMD indigenously develops and launches revolutionary Dispojekt safety needle syringes in
Hyderabad and Vijayawada to curb the menace of NSI
HIV, the prevalence of needle stick injuries is also at the highest level. Studies
report an annual of 100,000 injuries caused by sharp objects among nurses in the UK as

Asked about clinical studies conducted to affirm safety and efficacy of Dispojekt safety
needle syringes, Mr Rajiv said, “Dispojekt syringes are a part of Safety Engineered Devices
(SED). Numerous clinical studies and evaluations have been conducted to assess the safety
and efficacy of syringes with safety needles. There are clinical trials which have proved that
the use of SED has reduced the incidence of needle stick injuries in healthcare workers” and
its usage is encouraged as best practices for Injection Safety in EU & USA and by WHO in
the developing world. This initial design was field trialed in India, UK and USA and based on
feedback received the product was re-engineered to be more cost effective and affordable
and user friendly, by being a major improvement over existing commonly available safety
syringes in the global market.
“One such publication in the European Journal of Microbiology and Immunology, a German
study confirms that the uses of SED have reduced NSIs by 17.6 %. Another study published
in the British Journal of Nursing in 2020 confirms the above fact that SED reduces NSI. It’s
important to note that research in the medical field is ongoing, and new studies may have
been conducted yet to get published or under review,” Mr Rajiv added.
The launch of Dispojekt safety needle syringes, an innovative and cost-effective product
from the R&D lab of the world’s largest manufacturer of Auto-Disable (AD)
syringes, assumes significance in view of the monstrous magnitude of NSIs among the
health workers.

Glenmark Ranks Number 1 in Dermatologist Prescriptions for Protective Emollients Category and Prescribing Derma Therapy,as per IQVIA MAT Dec 2023

Telugu super news,Mumbai, 20th March, 2024 – Glenmark Pharmaceuticals Ltd. (Glenmark), a research-led, global pharmaceutical company, has been ranked number 1 in dermatologists’ prescriptions in the protective emollients category and for prescribing derma therapy. This is based on the IQVIA medical audit for MAT Dec 2023 (as per Projected Prescriptions) in India. Projected prescriptions figures are for the period from Jan 2023 to Dec 2023.

Key products in Glenmark’s dermatology portfolio including Episoft®, Candid Dusting Powder®, Momate®, Canditral SB®, La Shield®, Scalpe®+, Tacroz® ointment, etc. have made significant strides in providing effective solutions for multiple dermatological conditions. The Company’s flagship brand Candid® Powder delivered revenue growth of 20% for Q3 FY24. La Shield® portfolio delivered YoY revenue growth of 20%, while Scalpe®+ portfolio witnessed YoY revenue growth of 12.2% in Q3 FY24.

Mr. Alok Malik, President and Business Head – India Formulations at Glenmark Pharmaceuticals Ltd, said, “We are very excited to be ranked number 1 by prescription in the dermatology therapy as per IQVIA. Our strategic focus and expertise in dermatology reflect our commitment to advancing dermatological care and addressing a broad spectrum of skin health needs of patients in India. Leveraging a robust derma portfolio that spans a wide array of treatments, Glenmark is at the forefront of addressing both common and complex skin conditions.”

Glenmark continues to outperform the market in the Dermatology segment. In the market analysis ending December 2023, the dermatology sector in Indian Pharmaceutical Market (IPM) grew 6.2% on a moving annual total (MAT) basis. GPL outperformed the overall market with a dermatology value growth of 9.9%. With a market share of 7.49% in the dermatology sector as per MAT Dec 2023.

Alarming Rise of Heart Attacks in Hyderabad Youth: Is Obesity the Culprit?

Telugu super news,Hyderabad, March 7th, 2024: There has been a tremendous rise in heart ailments and sudden heart attacks, especially among the youth in Hyderabad. As per the Indian Heart Association, heart diseases are detected at an earlier age in India (almost 33% earlier) than other demographics, often without warning. Some of the major causes are linked to sedentary behaviour, engaging in strenuous work, high levels of stress, and long desk hours.

One of the leading causes of such heart attacks among youth is the deposition of cholesterol in blood vessels, due to obesity. The latest Lancet report also claimed that Telangana has over 25% central obesity and hypertension cases. The incidence of hypertriglyceridemia (high levels of triglycerides/fat deposits in the blood), is also high among patients in Telangana.

On World Obesity Day, Dr. R K Jain, Senior Interventional Cardiologist, KIMS Hospital, Hyderabad explains in detail about the same, “Obesity itself can directly harm the heart, even in the absence of known risk factors like high blood pressure, cholesterol, or diabetes. It is important to undertake proactive measures, especially among youth, who often engage in low physical activity and consume excessive processed foods.”

Obese individuals require more blood supply to supply oxygen and nutrients to their bodies, causing an increase in blood pressure. Additionally, obesity can lead to a build-up of fatty material in the arteries, leading to a heart attack. Research also indicates that higher Body mass index (BMI) was strongly linked to higher troponin levels, a protein found in the muscles of the heart. It is stated that people who are obese and have high troponin levels are nine times more likely to develop heart failure than those who had normal weight and undetectable troponin.

Commenting on the treatment modalities that patients should consider, Dr. Jain added, “These patients require tailored care

SANOY: Celebrating Hyderabad’s Heritage of Authenticity

Telugu super news, Hyderabad, March 1st,2024:In Hyderabad, a city where heritage and authenticity are woven into the very fabric of everyday life, SANOY finds a harmonious home. This launch in Hyderabad is a tribute to the city’s enduring spirit of genuine self-expression, mirroring SANOY’s core belief in “Wearing Your True Skin.”

Today marks a new chapter in the beauty industry as SANOY, the latest offering
from Heugah Luxury Goods Private Limited, unveils its groundbreaking skincare
line. SANOY stands as a testament to the inherent beauty within each individual,
advocating for a skincare routine that is genuine, effective, and unpretentious.

In an era where beauty standards are often dictated by unrealistic expectations,
SANOY takes a stand to declutter the chaos. It redefines beauty as an experience of
self-appreciation and natural allure. Each product in the SANOY range is
meticulously formulated with the purest ingredients, ensuring that they not only
care for the skin but also for the well-being of the individual.

‘Our goal is to cut through the noise,’ states Bhanumurty Kolluru, CEO, at Heugah
Luxury Goods. ‘SANOY is about embracing the skin you’re in. It’s about nourishing
your true self without the facade of needless complexity.’

The beauty sector is often captivated by the allure of the new and unconventional.
However, the COO of Heugah Luxury Goods Private Limited Mr. Bhanu Kolluru,
believes that true innovation lies in embracing the essentials. While brands like
Loreal and Garnier have pioneered remarkable advances, SANOY is here to remind
us that the foundation of genuine skincare remains unchanged—pure, simple, and
effective. It’s about embracing the beauty of reality, the comfort of simplicity, and
the integrity of products that serve our true needs.

The SANOY range is a curated collection of skincare essentials, free from the
hyperbolic claims that saturate the market. From rejuvenating night creams to
protective day creams, each product is a celebration of what truly matters in
skincare – nourishment, protection, and the celebration of one’s true self.

SANOY is committed to transparency, sustainability, and simplicity. It stands as a
beacon for those who seek to wear their skin with pride and confidence,
undistorted by the filters of contemporary beauty narratives.
‘We’re not just launching products. We’re launching a belief. A belief that beauty is
not about alteration but about revelation,’ adds Mr. Bhanumurty Kolluru.
As SANOY graces the shelves of Hyderabad’s esteemed retailers, we invite you to
embark on a journey of self-discovery and embrace your inherent beauty. Discover
more about SANOY’s commitment to authentic skincare by visiting
Together with the vibrant spirit of Hyderabad, SANOY celebrates the genuine
essence of “Wearing Your True Skin.”

Heugah Luxury Goods Private Limited
Heugah Luxury Goods Private Limited (HLGPL) charts a unique course in the luxury
domain, delving into the depths of human emotions and the rich tapestry of life’s
myriad experiences. Far removed from the conventional confines of fashion, HLGPL
is dedicated to forging profound connections, celebrating the authenticity and
emotional resonance that underpin our very existence.
With the launch of Sanoy, HLGPL’s inaugural brand, the company embarks on a
journey to transform intangible emotions into tangible expressions, making every
product a reflection of the genuine, unarticulated connections that bind us. HLGPL
stands as a testament to an ethos that values more than just the aesthetic appeal
of luxury—it champions the stories, dreams, and desires that resonate with our
collective human spirit, making every HLGPL creation, starting with Sanoy, a beacon
of true expression in the luxury landscape.

1 2 3 24